




PARENTERAL DRUGS (INDIA) LTD.



Dated: 30th May, 2013

To,
The National Stock Exchange of India Limited
Exchange Plaza,
Plot No. C/1, G Block,
Bandra Kurla Complex
Bandra(E), Mumbai-400 051

Sub: Submission of Audited financial results for the financial year ended on 31st March, 2013.

Dear Sir

Please find enclosed the Audited financial results of the Company for financial year ended on 31st March, 2013 duly taken on record by the Board of Directors of the Company at their meeting held on 30th May, 2013.

This is for the information of the Exchange and members thereof.

Kindly take the same on record and oblige.

Thanking You
Yours Sincerely
For Parenteral Drugs (India) Limited

Company Secretary

PARENTERAL DRUGS (INDIA) LIMITED

Regd. Office: 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (W) Mumbai (Maharashtra)

AUDITED STANDLONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MARCH, 2013

PART - I					(Rs in Lacs)	
Sr. No.	Particulars	3 Months Ended			Year Ended	Year Ended
		March 2013	December 2012	March 2012	March 2013	March 2012
		Audited	Unaudited	Audited	Audited	Audited
1	(a) Net Sales/Income from Operations (Net of Excise Duty)	5186.88	3901.19	5213.74	18721.55	22,256.08
	(b) Other Operating Income	2.28	2.21	-41.23	13.74	27.65
	Total Income From Operation (Net)	5,189.16	3,903.40	5,172.51	18,735.29	22,283.73
2	Expenditure					
	a) Consumption of Material Consumed	4622.22	1557.67	1099.02	10018.2	10,696.92
	b) Purchase of Stock In Trade					
	c) Change in Inventories of Finished Goods, Work in Progress and Stock In trade	-598.47	267.25	2019.86	1720.37	739.62
	d) Employee Benefit Expenses	214.63	449.98	617.13	1736.48	1,987.84
	e) Depreciation and Amortisation Expenses	443.84	430.00	464.27	1733.84	1284.43
	f) Other Expenditure (Any Item Exceeding 10% of the Total expenses relating to continuing operations to be shown separately	1371.81	2016.48	2965.30	7473.95	7,976.07
	Total Expenses	6054.03	4721.38	7165.58	22682.84	22684.88
3	Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	(864.87)	(817.98)	(1,993.07)	(3,947.55)	(401.15)
4	Other Income	0.00	0.00	0.00	0.00	-
5	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 + 4)	(864.87)	(817.98)	(1,993.07)	(3,947.55)	(401.15)
6	Finance costs	727.04	1184.32	1200.81	4222.44	3,919.01
7	Profit after interest but before Exceptional items (5-6)	(1,591.91)	(2,002.30)	(3,193.88)	(8,169.99)	(4,320.16)
8	Exceptional items	0.00	0.00	0.00	0.00	0.00
9	Profit / (Loss) from ordinary activities before tax	(1,591.91)	(2,002.30)	(3,193.88)	(8,169.99)	(4,320.16)
10	Tax Expenses	199.54	50	306.19	349.54	461.44
11	Net Profit / (Loss) from ordinary activities after tax (9 + 10)	(1,791.45)	(2,052.30)	(3,500.07)	(8,519.53)	(4,781.60)
12	Extraordinary items (net of tax expense) Lakhs)	0.00		0.00	0.00	0.00
13	Net Profit / (Loss) for the period (11 + 12)	(1,791.45)	(2,052.30)	(3,500.07)	(8,519.53)	(4,781.60)
14	Share of profit / (loss) of associates*					
15	Minority interest *					
16	Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13 + 14 + 15) *	(1,791.45)	(2,052.30)	(3,500.07)	(8,519.53)	(4,781.60)
17	Paid-up equity share capital (Face Value of the Share shall be indicated)	2586.68	2586.68	2586.86	2586.68	2586.68
18	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year				16848.8	22,698.33
19 i	Earnings per share (before extraordinary items) (of Rs 10/- each) (not annualised):					
	(a) Basic	(6.93)	(7.93)	(13.53)	(32.94)	(18.49)
	(b) Diluted	(6.93)	(7.93)	(13.53)	(32.94)	(18.49)
19 ii	Earnings per share (After extraordinary items) (of Rs 10/- each) (not annualised):					
	(a) Basic	(6.93)	(7.93)	(13.53)	(32.94)	(18.49)
	(b) Diluted	(6.93)	(7.93)	(13.53)	(32.94)	(18.49)

* Applicable in the case of consolidated results.

Note: The classification / disclosure of items in the financial results shall be in accordance with the Revised Schedule VI of the Companies Act, 1956.
Further to the above, profit/loss from discontinuing operations, if any, included in the above shall be disclosed with details thereof.

3/5

PART -II

A PARTICULARS OF SHAREHOLDING						
1	Public Shareholding					
	-No. of Shares	7,944,924	7,944,924	7,944,924	7,944,924	7,944,924
	-Percentage of shareholding	30.71%	30.71%	30.71%	30.71%	30.71%
2	Promoters and Promoter Group Shareholding **					
	a) Pledged/Encumbered					
	-No. of shares	17,921,907	17,921,907	7,378,799	17,921,907	7,378,799
	-Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100.00%	100.00%	41.17%	100.00%	41.17%
	-Percentage of Shares (as a % of the total share capital of the Company)	69.29%	69.29%	28.53%	69.29%	28.53%
	b) Non-encumbered					
	-No. of shares			10,543,108		10,543,108
	-Percentage of Shares (as a % of the total shareholding of promoter and promoter group)			58.83%		58.83%
	-Percentage of Shares (as a % of the total share capital of the Company)			40.76%		40.76%
B Detail of Investor Compliant 3 months ended (31.03.2013)						
	Pending at the beginning of the quarter	0				
	Received during the quarter	4				
	Disposed of during the quarter	4				
	Remaining unresolved at the end of the quarter	0				

Statement of Assets and Liabilities

Sr. No.	Particulars	31.3.2013 Audited	31.3.2012 Audited
A	EQUITY AND LIABILITIES		
1	Shareholders' funds		
	(a) Share Capital	3774.09	3232.89
	(b) Reserves and Surplus	17080.35	22818.55
	Sub-total - Shareholders' funds	20854.44	26051.44
2	Share application money pending allotment	0.00	2822.67
3	Minority interest *		
4	Non-current liabilities		
	(a) Long-term borrowings	30564.47	14951.75
	(b) Deferred tax liabilities (net)	2377.51	2027.97
	Sub-total - Non-current liabilities	32941.98	16979.72
5	Current liabilities		
	(a) Short-term borrowings	5025.68	12096.65
	(b) Trade payables	3927.26	6142.55
	(c) Other current liabilities	94.49	124.19
	(d) Short-term provisions	398.01	361.80
	Sub-total - Current liabilities	9445.44	18725.19
	TOTAL - EQUITY AND LIABILITIES	63241.86	64579.02
B	ASSETS		
1	Non-current assets		
	(a) Fixed assets	32841.14	33829.45
	(b) Non-current investments	13964.07	13964.07
	(c) Long-term loans and advances	2397.39	2896.64
	(d) Other non-current assets	0.64	0.64
	Sub-total - Non-current assets	49203.24	50690.80
2	Current assets		
	(a) Inventories	3626.68	5363.88
	(b) Trade receivables	7762.97	6815.27
	(c) Cash and cash equivalents	530.92	732.09
	(d) Short-term loans and advances	1898.24	761.97
	(e) Other current assets	219.81	215.01
	Sub-total - Current assets	14038.62	13888.22
	TOTAL - ASSETS	63241.86	64579.02

NOTES :

- The above results were reviewed by statutory auditors and audit committee of the company and approved by Board of Directors in their meeting held on 30th May 2013.
- The Company had approached the lender banks for restructuring of its loans with the CDR mechanism. The final package as approved by CDR EG has been finally implemented on 1st January 2013.
- The Company is engaged in the Pharmaceuticals business only and therefore, there is only one reportable segment in accordance with the Accounting Standard on Segment Accounting (AS-17).
- The figures for the quarter ended March 31, 2013 and March 31, 2012 are the balancing figures between audited figures in respect of the full financial year ended March 31, 2013 and March 31, 2012 respectively and the unaudited published year to date figures upto December 31, 2012 and December 31, 2011 respectively, being the end of the third quarter of the respectively financial years, which were subjected to a limited review.
- The previous year/period have been regrouped/rearranged wherever found necessary.
- The standalone financial results of the company are available on the website of the company i.e. www.pdindia.com and on the website of BSE (www.bseindia.com) and NSE (www.nseindia.com).

Place: Indore
Date: 30th May 2013

For and on behalf of Board of Directors
---sd-----
Manohar Lal Gupta
Chairman cum Managing Director



4/5

PARENTERAL DRUGS (INDIA) LIMITED

AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MARCH, 2013

PART - I		(Rs in Lacs)				
Sr. No.	Particulars	3 Months Ended			Year Ended	Year Ended
		March 2013	December 2012	March 2012	March 2013	March 2012
		Audited	Unaudited	Audited	Audited	Audited
1	Income from operation (a) Net Sales/Income from Operations (Net of Excise Duty) (b) Other Operating Income Total Income From Operation (Net)	11450.11 6.13 11,456.24	6893.88 3.21 6,897.09	8147.11 -103.35 8,043.76	32742.72 24.51 32,767.23	33,251.00 43.91 33,294.91
2	Expenditure a) Cost of Material Consumed b) Purchase of Stock In Trade c) Change in Inventories of Finished Goods, Work in Progress and Stock In trade d) Employee Benefit Expenses e) Depreciation and Amortisation Expenses f) Other Expenditure (Any Item Exceeding 10% of the Total expenses relating to continuing operations to be shown separately) Total Expenses	7361.87 -479.22 372.49 705.52 4161.98 12122.64	3911.29 -112.98 507.54 583.69 2950.13 7839.67	3032.63 2403.65 769.03 516.67 3784.63 10506.61	18508.5 901.36 2128.12 2299.58 12606.68 36444.24	17,349.83 1,154.74 2,462.27 1446.78 10,892.60 33306.22
3	Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	(666.40)	(942.58)	(2,462.85)	(3,677.01)	(11.31)
4	Other Income	0.00	0.00	0.00	0.00	-
5	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 + 4)	(666.40)	(942.58)	(2,462.85)	(3,677.01)	(11.31)
6	Finance costs	1199.00	1585.27	1570.72	5584.68	4,840.64
7	Profit/(Loss) from ordinary activities after finance costs but before Exceptional Items (5-6)	(1,865.40)	(2,527.85)	(4,033.57)	(9,261.69)	(4,851.95)
8	Exceptional items	0.00	0.00	0.00	0.00	0.00
9	Profit / (Loss) from ordinary activities before tax (7 + 8)	(1,865.40)	(2,527.85)	(4,033.57)	(9,261.69)	(4,851.95)
10	Tax Expenses	1296.93	83.16	190.99	1522.05	484.36
11	Net Profit / (Loss) from ordinary activities after tax (9 + 10)	(3,162.33)	(2,611.01)	(4,224.56)	(10,783.74)	(5,336.31)
12	Extraordinary Items (net of tax expense Lakhs)				0.00	0.00
13	Net Profit / (Loss) for the period (11 + 12)	(3,162.33)	(2,611.01)	(4,224.56)	(10,783.74)	(5,336.31)
14	Share of profit / (loss) of associates*				-	-
15	Minority interest *			1.51	-	1.51
16	Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13 + 14 + 15) *	(3,162.33)	(2,611.01)	(4,226.07)	(10,783.74)	(5,337.82)
17	Paid-up equity share capital (Face Value of the Share shall be indicated)	2586.68	2586.68	2586.68	2586.68	2586.68
18	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year				19078.14	27,080.12
19 i	Earnings per share (before extraordinary items) (of Rs 10/- each) (not annualised): (a) Basic (b) Diluted	(12.23) (12.23)	(10.09) (10.09)	(16.34) (16.34)	(41.69) (41.69)	(20.64) (20.64)
19 ii	Earnings per share (After extraordinary items) (of Rs 10/- each) (not annualised): (a) Basic (b) Diluted	(12.23) (12.23)	(10.09) (10.09)	(16.34) (16.34)	(41.69) (41.69)	(20.64) (20.64)

* Applicable in the case of consolidated results.

Note: The classification / disclosure of items in the financial results shall be in accordance with the Revised Schedule VI of the Companies Act, 1956.

Further to the above, profit/loss from discontinuing operations, if any, included in the above shall be disclosed with details thereof.

5/5

PART -II

A PARTICULARS OF SHAREHOLDING						
1	Public Shareholding					
	-Number of Shares	79,44,924	79,44,924	79,44,924	79,44,924	79,44,924
	-Percentage of shareholding	30.71%	30.71%	30.71%	30.71%	30.71%
2	Promoters and Promoter Group Shareholding **					
	a) Pledged/Encumbered					
	-Number of shares	1,79,21,907	1,79,21,907	73,78,799	1,79,21,907	73,78,799
	-Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100.00%	100.00%	41.17%	100.00%	41.17%
	-Percentage of Shares (as a % of the total share capital of the Company)	69.29%	69.29%	28.53%	69.29%	28.53%
	b) Non-encumbered					
	-Number of shares			1,05,43,108		1,05,43,108
	-Percentage of Shares (as a % of the total shareholding of promoter and promoter group)			58.83%		58.83%
	-Percentage of Shares (as a % of the total share capital of the Company)			40.76%		40.76%
B	Detail of Investor Compliant	3 months ended (31.03.2013)				
	Pending at the beginning of the quarter	0				
	Received during the quarter	4				
	Disposed of during the quarter	4				
	Remaining unresolved at the end of the quarter	0				

Statement of Assets and Liabilities

Sr. No.	Particulars	31.3.2013	31.3.2012
		Audited	Audited
A	EQUITY AND LIABILITIES		
1	Shareholders' funds		
	(a) Share Capital	4324.09	3782.89
	(b) Reserves and Surplus	19197.94	27200.34
	Sub-total - Shareholders' funds	23522.03	30983.23
2	Share application money pending allotment	1100.00	3922.67
3	Minority interest *	65.04	65.04
4	Non-current liabilities		
	(a) Long-term borrowings	40027.84	22302.03
	(b) Deferred tax liabilities (net)	3754.37	2253.89
	Sub-total - Non-current liabilities	43782.21	24555.92
5	Current liabilities		
	(a) Short-term borrowings	8364.00	15991.43
	(b) Trade payables	5971.64	7797.70
	(c) Other current liabilities	196.14	1158.50
	(d) Short-term provisions	531.38	475.38
	Sub-total - Current liabilities	15063.16	25423.01
	TOTAL - EQUITY AND LIABILITIES	83532.44	84949.87
B	ASSETS		
1	Non-current assets		
	(a) Fixed assets	48200.29	48406.58
	(b) Goodwill on consolidation *	13218.17	13218.17
	(c) Non-current investments	2.66	2.66
	(d) Long-term loans and advances	1471.54	2413.23
	(e) Other non-current assets	1430.23	1814.83
	Sub-total - Non-current assets	64322.89	65855.47
2	Current assets		
	(a) Inventories	6426.35	7390.98
	(b) Trade receivables	7895.03	9190.40
	(c) Cash and cash equivalents	1049.91	1332.78
	(d) Short-term loans and advances	3578.61	932.36
	(e) Other current assets	259.65	247.88
	Sub-total - Current assets	19209.55	19494.40
	TOTAL - ASSETS	83532.44	85349.87

NOTES :

- The above results were reviewed by statutory auditors and audit committee of the company and approved by Board of Directors in their meeting held on 30th May 2013
- The financial results of the subsidiary companies have been consolidated.
- The Company is engaged in the Pharmaceuticals business only and therefore, there is only one reportable segment in accordance with the Accounting Standard on Segment Accounting (AS-17).
- The figures for the quarter ended March 31, 2013 and March 31, 2012 are the balancing figures between audited figures in respect of the full financial year ended March 31, 2013, and March 31, 2012 respectively and the unaudited published year to date figures upto December 31, 2012 and December 31, 2011 respectively, being the end of the third quarter of the respectively financial years, which were subjected to a limited review.
- The previous year/period have been regrouped/rearranged wherever found necessary.
- The standalone financial results of the company are available on the website of the company i.e. www.pdindia.com and on the website of BSE (www.bseindia.com) and NSE (www.nseindia.com). The key standalone financial results are given below:

Sr. No.	Particulars	Quarter Ended		Year Ended		Year Ended	
		Audited	Unaudited	Audited	Audited	Audited	Audited
		31.03.2013	31.12.2012	31.03.2012	31.03.2013	31.03.2012	31.03.2012
1	Income from operations & other income	5,189.16	3,903.40	5,172.51	18,735.29	22,283.73	
2	Profit/Loss before tax	(1,591.91)	(2,002.30)	(3,193.88)	(8,169.99)	(4,320.16)	
3	Profit/Loss after tax	(1,791.45)	(2,052.30)	(3,500.07)	(8,519.53)	(4,781.60)	

For and on behalf of Board of Directors

Place: Indore
Date: 30th May 2013

sd/
Manohar Lal Gupta
Chairman cum Managing Director

